Common mutations in the phosphofructokinase-M gene in Ashkenazi Jewish patients with glycogenesis VII--and their population frequency
- PMID:8037209
- PMCID: PMC1918380
Common mutations in the phosphofructokinase-M gene in Ashkenazi Jewish patients with glycogenesis VII--and their population frequency
Abstract
Phosphofructokinase (PFK) catalyzes the rate-limiting step of glycolysis. Deficiency of the muscle enzyme is manifested by exercise intolerance and a compensated hemolytic anemia. Case reports of this autosomal recessive disease suggest a predominance in Ashkenazi Jews in the United States. We have explored the genetic basis for this illness in nine affected families and surveyed the normal Ashkenazi population for the mutations we have found. Genomic DNA was amplified using PCR, and denaturing gradient-gel electrophoresis was used to localize exons with possible mutations. The polymorphic exons were sequenced or digested with restriction enzymes. A previously described splicing mutation, delta 5, accounted for 11 (61%) of 18 abnormal alleles in the nine families. A single base deletion leading to a frameshift mutation in exon 22 (delta C-22) was found in six of seven alleles. A third mutation, resulting in a nonconservative amino acid substitution in exon 4, accounted for the remaining allele. Thus, three mutations could account for all illness in this group, and two mutations could account for 17 of 18 alleles. In screening 250 normal Ashkenazi individuals for all three mutations, we found only one delta 5 allele. Clinical data revealed no correlation between the particular mutations and symptoms, but male patients were more symptomatic than females, and only males had frank hemolysis and hyperuricemia. Because PFK deficiency in Ashkenazi Jews is caused by a limited number of mutations, screening genomic DNA from peripheral blood for the described mutations in this population should enable rapid diagnosis without muscle biopsy.
Similar articles
- Nonsense mutation in the phosphofructokinase muscle subunit gene associated with retention of intron 10 in one of the isolated transcripts in Ashkenazi Jewish patients with Tarui disease.Vasconcelos O, Sivakumar K, Dalakas MC, Quezado M, Nagle J, Leon-Monzon M, Dubnick M, Gajdusek DC, Goldfarb LG.Vasconcelos O, et al.Proc Natl Acad Sci U S A. 1995 Oct 24;92(22):10322-6. doi: 10.1073/pnas.92.22.10322.Proc Natl Acad Sci U S A. 1995.PMID:7479776Free PMC article.
- Various classes of mutations in patients with phosphofructokinase deficiency (Tarui's disease).Raben N, Sherman JB, Adams E, Nakajima H, Argov Z, Plotz P.Raben N, et al.Muscle Nerve Suppl. 1995;3:S35-8. doi: 10.1002/mus.880181409.Muscle Nerve Suppl. 1995.PMID:7603525
- A 5' splice junction mutation leading to exon deletion in an Ashkenazic Jewish family with phosphofructokinase deficiency (Tarui disease).Raben N, Sherman J, Miller F, Mena H, Plotz P.Raben N, et al.J Biol Chem. 1993 Mar 5;268(7):4963-7.J Biol Chem. 1993.PMID:8444874
- Mutations in muscle phosphofructokinase gene.Raben N, Sherman JB.Raben N, et al.Hum Mutat. 1995;6(1):1-6. doi: 10.1002/humu.1380060102.Hum Mutat. 1995.PMID:7550225Review.
- Cystic fibrosis in Jews: frequency and mutation distribution.Kerem B, Chiba-Falek O, Kerem E.Kerem B, et al.Genet Test. 1997;1(1):35-9. doi: 10.1089/gte.1997.1.35.Genet Test. 1997.PMID:10464623Review.
Cited by
- Nonsense mutation in the phosphofructokinase muscle subunit gene associated with retention of intron 10 in one of the isolated transcripts in Ashkenazi Jewish patients with Tarui disease.Vasconcelos O, Sivakumar K, Dalakas MC, Quezado M, Nagle J, Leon-Monzon M, Dubnick M, Gajdusek DC, Goldfarb LG.Vasconcelos O, et al.Proc Natl Acad Sci U S A. 1995 Oct 24;92(22):10322-6. doi: 10.1073/pnas.92.22.10322.Proc Natl Acad Sci U S A. 1995.PMID:7479776Free PMC article.
- Skeletal muscle disorders of glycogenolysis and glycolysis.Godfrey R, Quinlivan R.Godfrey R, et al.Nat Rev Neurol. 2016 Jul;12(7):393-402. doi: 10.1038/nrneurol.2016.75. Epub 2016 May 27.Nat Rev Neurol. 2016.PMID:27231184Review.
- PFKM gene defect and glycogen storage disease GSDVII with misleading enzyme histochemistry.Auranen M, Palmio J, Ylikallio E, Huovinen S, Paetau A, Sandell S, Haapasalo H, Viitaniemi K, Piirilä P, Tyynismaa H, Udd B.Auranen M, et al.Neurol Genet. 2015 Jun 4;1(1):e7. doi: 10.1212/NXG.0000000000000007. eCollection 2015 Jun.Neurol Genet. 2015.PMID:27066546Free PMC article.
- Deficiency of phosphofructo-1-kinase/muscle subtype in humans impairs insulin secretion and causes insulin resistance.Ristow M, Vorgerd M, Möhlig M, Schatz H, Pfeiffer A.Ristow M, et al.J Clin Invest. 1997 Dec 1;100(11):2833-41. doi: 10.1172/JCI119831.J Clin Invest. 1997.PMID:9389749Free PMC article.
- Geographic distribution of disease mutations in the Ashkenazi Jewish population supports genetic drift over selection.Risch N, Tang H, Katzenstein H, Ekstein J.Risch N, et al.Am J Hum Genet. 2003 Apr;72(4):812-22. doi: 10.1086/373882. Epub 2003 Feb 24.Am J Hum Genet. 2003.PMID:12612865Free PMC article.
References
MeSH terms
Substances
Associated data
- Actions
Related information
LinkOut - more resources
Full Text Sources